This study has 8 locations in USA - 11 Dec `20Evaluation of AMG 714 for Vitiligo (REVEAL)

Evaluation of AMG 714 for Vitiligo (REVEAL)

Official title: Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI)

Description:

The AMG 714 for Vitiligo (REVEAL Trial), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), is a Phase 2 clinical study evaluating the efficacy and safety of AMG 714, an anti-IL-15 monoclonal antibody, in adults with vitiligo. The trial aims to determine if AMG 714, combined with narrowband ultraviolet B (nbUVB) phototherapy, can effectively restore skin pigmentation by modulating the immune response responsible for melanocyte destruction.

This is an active study which is not recruiting new patients.

 

Start date: December 11, 2020

Completion date: May 30, 2025

Contact: Brett A. King, MD, PhD

Link: https://clinicaltrials.gov/study/NCT04338581

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Evaluation of AMG 714 for Vitiligo (REVEAL) . By submitting you agree to our Privacy Policy.

FAQOther Questions